CHARACTERIZATION OF NOVEL NUCLEOSIDE ANALOG DRUGS AGAINST HSV-1 INFECTION
公开可下载的内容
open in viewerInfection with Herpes Simplex Virus-1 (HSV-1) is common in humans, and can lead to severe symptoms if drug resistance occurs. This project aimed to select a novel nucleoside analog showing potential as an HSV-1 antiviral therapy, and to begin to characterize its mechanism of action. Using plaque reduction and MTS assays, compound MBX 2168 was identified as a potential candidate with strong antiviral activity and low toxicity. Mutational studies of 3 viral kinases and kinetic studies of human 2-deoxyguanosine kinase (dGK) suggest that MBX 2168 is not initially phosphorylated by those viral kinases and is not phosphorylated by human dGK. Sequence analysis and molecular modeling of an HSV-1 strain resistant to MBX 2168 suggest that the drug works by inhibiting HSV-1 DNA synthesis.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- 贡献者
- Publisher
- Identifier
- E-project-042612-131319
- Advisor
- Year
- 2012
- Sponsor
- Date created
- 2012-04-26
- Resource type
- Major
- Rights statement
- 最新修改
- 2023-09-27
关系
- 属于 Collection:
项目
Permanent link to this page: https://digital.wpi.edu/show/0g354h16n